Algorithm to assess causality after individual adverse events following immunizations

Vaccine

Volumn 30, Issue 39, 2012, Pages 5791-5798

  Halsey, Neal A ^a   Edwards, Kathryn M ^b   Dekker, Cornelia L ^c   Klein, Nicola P ^d   Baxter, Roger ^d   LaRussa, Philip ^e   Marchant, Colin ^f   Slade, Barbara ^g   Vellozzi, Claudia ^g  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d KAISER PERMANENTE   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f BOSTON MEDICAL CENTER   (United States)

^g CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Adverse events; Algorithm; Causality; Vaccine safety; Vaccines

Indexed keywords

ACICLOVIR; ANTHRAX VACCINE; CEFUROXIME; CLARITHROMYCIN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; MENINGOCOCCUS VACCINE; TETANUS TOXOID; VACCINE; VANCOMYCIN; YELLOW FEVER VACCINE;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ADVERSE EVENT FOLLOWING IMMUNIZATION; ADVERSE OUTCOME; ANGIONEUROTIC EDEMA; ARTICLE; CAUSAL ATTRIBUTION; DRUG FEVER; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FALSE POSITIVE RESULT; GUILLAIN BARRE SYNDROME; HEALTH CARE PERSONNEL; HUMAN; HYPERSENSITIVITY REACTION; IMMUNIZATION; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; INJECTION SITE SWELLING; LUMBAR PUNCTURE; MENINGITIS; NERVE INJURY; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SORE THROAT; SUDDEN INFANT DEATH SYNDROME; THORAX PAIN; UNSPECIFIED SIDE EFFECT; URTICARIA;

ALGORITHMS; CAUSALITY; HUMANS; IMMUNIZATION; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84865041860     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.04.005     Document Type: Article

References (51)

1. National Immunization Program CDC Achievements in public health, 1900-1999: impact of vaccines universally recommended for children - United States, 1900-1998. MMWR Morbidity and Mortality Weekly Report 1999, 48:243-248.
2. Iannelli V. Understanding vaccine safety. Updated December 3, 2003. Available at: (accessed July 20, 2012). http://www.pediatrics.about.com/cs/immunizations/a/vaccine_safety.htm.
3. Ellenberg S.S., Braun M.M. Monitoring the safety of vaccines: assessing the risks. Drug Safety 2002, 25(3):145-152.
4. Halsey N.A. The science of evaluation of AEs associated with vaccination. Seminars in Pediatric Infectious Diseases 2002, 13(3):205-214.
5. Wise R.P., Kiminyo K.P., Salive M.E. Hair loss after routine immunizations. JAMA 1997, 278(14):1176-1178.
6. Angel J.B., Walpita P., Lerch R.A., et al. Vaccine-associated measles pneumonitis in an adult with AIDS. Annals of Internal Medicine 1998, 129(2):104-106.
7. Rothman K.J., Causation Greenland S. Causal Inference in Epidemiology. American Journal of Public Health 2005, 95:S144-S150.
8. Coggon D.I., Martyn C.N. Time and chance: the stochastic nature of disease causation. Lancet 2005, 365(9468):1434-1437.
9. Institute of Medicine Adverse effects of vaccines: evidence and causality 2011, National Academy Press, Washington, DC. K.R. Stratton, A. Ford, E. Rusch, E.W. Clayton (Eds.).
10. LaRussa P.S., Edwards K.M., Dekker C.L., et al. Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment Network. Pediatrics 2011, 127(Suppl. 1):S65-S73.
11. Arimone Y., Begaud B., Miremont-Salame G Agreement of expert judgment in causality assessment of adverse drug reactions. European Journal of Clinical Pharmacology 2005, 61:169-173.
12. WHO Causality assessment of AEs following immunization. Weekly Epidemiological Record 2001, 76(12):85-89.
13. WHO. Immunization safety. Last updated April 6, 2009. Available at: (accessed July 20, 2012). http://www.who.int/immunization_safety/en/.
14. Brighton Collaboration. Available definitions available at: (accessed July 20, 2012). https://brightoncollaboration.org/public/what-we-do/standards/case-defin itions/available-definitions.html.
15. Slade B.A., Leidel L., Vellozzi C., et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009, 302(7):750-757.
16. Vellozzi C., Broder K.R., Haber P., et al. AEs following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine AE Reporting System, United States, October 1, 2009-January 31, 2010. Vaccine 2010, 28(45):7248-7255.
17. Varricchio F., Iskander J., Destefano F., et al. Understanding vaccine safety information from the Vaccine AE Reporting System. Pediatric Infectious Disease Journal 2004, 23(4):287-294.
18. Institute of Medicine Adverse effects of vaccines: evidence and causality 2011, National Academy Press, Washington, DC, pp. 19-34. K.R. Stratton, A. Ford, E. Rusch, E.W. Clayton (Eds.).
19. Institute of Medicine Adverse events associated with childhood vaccines: evidence bearing on causality 1994, National Academy Press, Washington, DC. K.R. Stratton, C.J. Howe, R.B. Johnston (Eds.).
20. National Vaccine Injury Compensation Program. About VICP. Available at: (accessed July 20, 2012). http://www.hrsa.gov/vaccinecompensation.
21. Cook K.M., Evans E. The National Vaccine Injury Compensation Program. Pediatrics 2011, 127:S74-S77.
22. Deloria M.A., Blackwelder W.C., Decker M.D., et al. Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations. Pediatrics 1995, 96(3 Pt 2):592-594.
23. Klein N.P., Edwards K.M., Sparks R.C., Dekker C.L. Recurrent sterile abscesses following aluminum adjuvant-containing vaccines. BMJ Case Reports 2009, 200:9. 10.1136/bcr.09.2008.0951.
24. Bergfors E., Björkelund C., Trollfors B. Nineteen cases of persistent pruritic nodules and contact allergy to aluminium after injection of commonly used aluminium- adsorbed vaccines. European Journal of Pediatrics 2005, 164:691-697.
25. Sikand V.K., Halsey N., Krause P.J., et al. Safety and immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme disease in healthy children and adolescents: a randomized controlled trial. Pediatrics 2001, 108(1):123-128.
26. Rennels M.B., Deloria M.A., Pichichero M.E., et al. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics 2000, 105(1):e12.
27. Burwen D.R., La Voie L., Braun M.M., Houck P., Evaluating Ball R. AEs after vaccination in the Medicare population. Pharmacoepidemiology and Drug Safety 2007, 16(7):753-761.
28. Klein N.P., Fireman B., Yih W.K., et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics 2010, 126(1):e1-e8.
29. Prevots D.R., Sutter R.W., Strebel P.M., Weibel R.E., Cochi S.L. Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991. Implications for estimating the risk of vaccine-associated disease. Archives of Pediatrics & Adolescent Medicine 1994, 148(5):479-485.
30. Wood R.A., Berger M., Dreskin S.C., et al. An algorithm for treatment of patients with hypersensitivity reactions after vaccines. Pediatrics 2008, 122(3):e771-e777.
31. Boyce J.A., Assa'ad A., Burks A.W., et al. Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report. Journal of Allergy and Clinical Immunology 2010, 126(6):1105-1118.
32. Khetsuriani N., Prevots D.R., Quick L., et al. Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. Journal of Infectious Diseases 2003, 188(12):1845-1852.
33. Ponvert C., Scheinmann P. Vaccine allergy and pseudo-allergy. European Journal of Dermatology 2003, 13(1):10-15.
34. Warrington R.J., Martens C.J., Rubin M., Rutherford W.J., Aoki F.Y. Immunologic studies in subjects with a serum sickness-like illness after immunization with human diploid cell rabies vaccine. Journal of Allergy and Clinical Immunology 1987, 79(4):605-610.
35. Griffin M.R., Ray W.A., Livengood J.R., Schaffner W. Risk of sudden infant death syndrome after immunization with the diphtheria-tetanus-pertussis vaccine. New England Journal of Medicine 1988, 319(10):618-623.
36. Ostfeld B.M., Esposito L., Perl H., Hegyi T. Concurrent risks in sudden infant death syndrome. Pediatrics 2010, 125(3):447-453.
37. Galea S.A., Sweet A., Beninger P., et al. The safety profile of varicella vaccine: a 10-year review. Journal of Infectious Diseases 2008, 197(Suppl. 2):S165-S169.
38. Pahud B.A., Glaser C.A., Dekker C.L., Arvin A.M., Schmid D.S. Varicella zoster disease of the central nervous system: epidemiological, clinical, and laboratory features 10 years after the introduction of the varicella vaccine. Journal of Infectious Diseases 2011, 203:316-323.
39. Yen C., Jakob K., Esona M.D., et al. Detection of fecal shedding of rotavirus vaccine in infants following their first dose of pentavalent rotavirus vaccine. Vaccine 2011, 29(24):4151-4155.
40. Stetler H.C., Garbe P.L., Dwyer D.M., et al. Outbreaks of group A streptococcal abscesses following diphtheria-tetanus toxoid-pertussis vaccination. Pediatrics 1985, 75(2):299-303.
41. Hutin Y., Hauri A., Chiarello L., et al. Best infection control practices for intradermal, subcutaneous, and intramuscular needle injections. Bulletin of the World Health Organization 2003, 81(7):491-500.
42. Sood D.K., Kumar S., Singh S., Sokhey J. Adverse reactions after measles vaccination in India. National Medical Journal of India 1995, 8(5):208-210.
43. Influenza Enserink M. Crisis underscores fragility of vaccine production system. Science 2004, 306(5695):385.
44. D'Souza Y., Fombonne E., Ward B.J. No evidence of persisting measles virus in peripheral blood mononuclear cells from children with autism spectrum disorder. Pediatrics 2006, 118(4):1664-1675.
45. Sever J.L., Brenner A.I., Gale A.D., Lyle J.M., Moulton L.H., West D.J., et al. Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Pharmacoepidemiology and Drug Safety 2002, 11(3):189-202.
46. Atanasoff S., Ryan T., Lightfoot R., Johann-Liang R. Shoulder injury related to vaccine administration (SIRVA). Vaccine 2010, 28(51):8049-8052.
47. Institute of Medicine Adverse effects of vaccines: evidence and causality 2011, National Academy Press, Washington, DC, p. 86. K.R. Stratton, A. Ford, E. Rusch, E.W. Clayton (Eds.).
48. Sejvar J.J., Kohl K.S., Bilynsky R., et al. Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007, 25(31):5771-5792.
49. Centers for Disease Control and Prevention (CDC) Transmission of yellow fever vaccine virus through breast-feeding - Brazil, 2009. MMWR. Morbidity and Mortality Weekly Report 2010, 59(5):130-132.
50. Kuhn S., Twele-Montecinos L., MacDonald J., Webster P., Law B. Case report: probable transmission of vaccine strain of yellow fever virus to an infant via breast milk. CMAJ 2011, 183(4):E243-E245.
51. Traiber C., Coelho-Amaral P., Ritter V.R., Winge A. Infant meningoencephalitis caused by yellow fever vaccine virus transmitted via breastmilk. Jornal de Pediatria (Rio J) 2011, 87(3):269-272.